Tu1885 EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN BIOLOGIC NAÏVE, BIOLOGIC NON-FAILURE, AND BIOLOGIC FAILURE POPULATIONS THROUGH 2 YEARS: UNIFI LONG-TERM EXTENSION
Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Colleen Marano(Johnson & Johnson (United States)), María T. Abreu(Icahn School of Medicine at Mount Sinai), Ramesh Arasaradnam(University Hospital Coventry), Rupert W. Leong(The University of Sydney), Yiying Zhou(Janssen (United States)), William J. Sandborn(University of San Diego), Tadakazu Hisamatsu(Kyorin University), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Silvio Danese(IRCCS Ospedale San Raffaele), David Rowbotham(University of Auckland), Hongyan Zhang(Tianjin University), Christopher D. O’Brien(Cedars-Sinai Medical Center), Ellen Scherl(NewYork–Presbyterian Hospital), Jewel Johanns(Johnson & Johnson (United States)), Remo Panaccione(University of Calgary)
Cited by 2
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k